KIYATEC to Present New Clinical Correlation Data at American Association for Cancer Research

GREENVILLE, S.C.--(BUSINESS WIRE)-- Kiyatec, the leader in clinically correlated, published functional precision oncology technology today announced that six abstracts were accepted for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022. The meeting will be held in New Orleans from April 8 – 13, 2022.

KIYATEC’s clinical and pre-clinical technology platforms, 3D Predict^TM and KIYA-PREDICT^TM, respectively, are leading the functional precision oncology space with published evidence of predictive response correlated to clinical outcomes. The six abstracts accepted for presentation at the conference include applications in multiple tumor types, immunotherapy drug response, and ex vivo application of PDX for pre-clinical drug development. These works feature collaborations with investigators from XenoSTART and the Adenoid Cystic Carcinoma Research Foundation.

“We are proud to showcase our research at the upcoming AACR conference,” said Tessa DesRochers, Ph.D., Chief Scientific Officer at KIYATEC. “The collection of abstracts demonstrates our dedication to leading with evidence. Our strong data demonstrates that our approach works.”

Session titles and information for the abstracts are listed below and are also available on the AACR online itinerary planner. KIYATEC will exhibit at AACR at Booth #1449.

KIYATEC presentation schedule:

Ex vivo 3D drug response profiling of XPDX-derived tumor cells for acceleration of preclinical drug development
3D models and Microfluidics, Section 9
April 10^th 1:30 – 5 PM

Ex vivo 3D culture of adenoid cystic carcinoma PDX models recapitulate disease biomarkers and predict drug response
3D models and Microfluidics, Section 9
April 10^th 1:30 – 5 PM

Engineered 3D tissues facilitate preclinical immunotherapy studies in fully human platforms
Tissue Recombinant, Organ slide, and Decellularized Models, Section 14
April 10^th 1:30 – 5 PM

3D Predict^TM, an analytically and clinically validated platform for evidence-based functional precision medicine
Biomarkers Predictive of Therapeutic Benefit, Section 31
April 12^th 9 AM – 12:30 PM

Organoids standardized to a clinically validated drugs response assay for truly predictive in vitro drug response profiling
Organoid-based models, Section 9
April 12^th 1:30 – 5 PM

Dissecting personalized PD-1 inhibitor efficacy using patient-derived 3D spheroids
Vaccines/Immunomodulatory Agents and Interventions, Section 34
April 13^th 9 AM – 12:30 PM

About KIYATEC

KIYATEC is a functional precision oncology company that measures the response of individual patient live cancer cells to inform oncologists’ treatment selection decisions. The company’s Clinical Services business offers clinical tests for high-grade glioma and ovarian cancers, and is developing tests for breast, non-small cell lung cancers and rare tumors in its CLIA-certified lab. The company’s Drug Development Services business works with leading biopharmaceutical companies to unlock response dynamics for their investigational drug candidates across the majority of solid tumor types.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005520/en/